The role of saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis in non-diabetic patients: A prospective observational study
Metabolic dysfunction-associated steatohepatitis (MASH) is a metabolic disease characterized by hepatic fat accumulation and significant inflammation. Patients with hepatic steatosis who also have at least one of the five cardiometabolic risk markers are considered to have metabolic dysfunction-associated steatotic liver disease. MASH is diagnosed when a microscopic examination of liver tissue reveals fat accumulation in hepatocytes along with inflammation and destruction of liver cells. This study aims to assess the role of saroglitazar, a dual proliferator peroxisome-activated receptor agonist, in the medical therapy of MASH in non-diabetic patients. A prospective observational study was carried out in a tertiary care facility in north India. A total of 51 non-diabetic MASH patients (males and females, 18 – 75 years of age, body mass index ≥18.5 kg/m2) were included in this study. Diagnosis of MASH was based on liver FibroScan (controlled attenuation parameter [CAP] score >238, liver stiffness measurement [LSM] value >7kPa) along with raised liver enzymes (serum glutamic-oxaloacetic transaminase [SGOT], serum glutamic-pyruvic transaminase [SGPT] > upper value of normal limits). All these 51 patients received 4 mg once-daily dose of saroglitazar for the treatment of MASH for 24 weeks. In this study, a standard treatment protocol was used. The percentage changes in aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, triglyceride, low-density lipoprotein (LDL), and LSM with CAP were evaluated using an analysis of variance test and multiple regression analysis. About 72.5% of these patients were male and 27.5% were female (male: female ratio of 2.6). The mean age of patients was 51 ± 13.13 years. Pre- and post-treatment values of different parameters were compared. Pre-treatment mean values of ALT and AST were 93.83 ± 6.16 U/L and 76.13 ± 4.1 U/L, respectively, while their post-treatment mean values were 32.97 ± 2.15 U/L and 34.57 ± 1.65 U/L, respectively (P-value for AST and ALT <0.001). In conclusion, saroglitazar is effective in the medical management of MASH by reducing liver stiffness and suppressing elevated liver enzymes (SGOT/SGPT) as well as serum LDL levels over 6 months.
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. doi: 10.1002/hep.25762
- Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-690. doi: 10.1038/nrgastro.2013.171
- Targher G, Byrne CD. Clinical review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2015;100(6):1887-1901. doi: 10.1210/jc.2012-3093
- Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10(11):645-655. doi: 10.1038/nrgastro.2013.182
- Sanyal AJ, Friedman SL, McCullough A, Dimick-Santos L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2018;67(2):549-569. doi: 10.1002/hep.27678
- Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147-1159.e5.
- Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med. 2016;165(5):305-315. doi: 10.7326/M15-1774
- Kersten S, Stienstra R. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie. 2017;136:75-84. doi: 10.1016/j.biochi.2016.12.019
- Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297-2307. doi: 10.1056/NEJMoa060326
- Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. doi: 10.1056/NEJMoa0907929
- Loomba R, Sirlin CB, Schwimmer JB, Lavine JE, Holty JE. How much variance in biopsy‐proven nonalcoholic fatty liver disease can be explained by established risk factors? Hepatology. 2018;67(3):846-856.
- Kaur S, Kapoor R. Emerging strategies in the treatment of non-alcoholic steatohepatitis. World J Gastrointest Pharmacol Therapeut. 2020;11(3):16-27.
- Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR study. Hepatology. 2020;72(3):892-905. doi: 10.1002/hep.31108
- Sanyal AJ. Saroglitazar for nonalcoholic steatohepatitis: A randomized controlled double-blind trial. Hepatology. 2020;72(2), 719-731.
- Ratziu V. Saroglitazar, a PPAR-α/γ agonist, for treatment of non-alcoholic fatty liver disease: A randomized double-blind placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3(12):855-865.
- Aithal GP. Saroglitazar for the treatment of nonalcoholic steatohepatitis: A randomized controlled trial. J Hepatol. 2016;65(2):289-295.
- Sharma M. Long-term effects of saroglitazar on NASH and fibrosis in non-diabetic patients: A multicenter observational study. J Clin Gastroenterol. 2019;53(3):243-249.
- Kumar S. Saroglitazar in nonalcoholic fatty liver disease: A real-world observational study. Diabetes Obes Metab. 2017;19(5):721-724.
- Goyal O, Nohria S, Goyal P, et al. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: A prospective, observational, realworld study. Nat Res. 2020;10:21117. doi: 10.1038/s41598-020-78342-x
- Kaul U, Parmar D, Manjunath K, et al. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: Integrated analysis of the real-world evidence. Cardiovasc Diabetol. 2019;18:80. doi: 10.1186/s12933-019-0884-3
- Kumar DP, Caffrey R, Marioneaux J, et al. The PPAR α/γ agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci Rep. 2020;10:9330. doi: 10.1038/s41598-020-66458-z
- Sarin SK. A prospective, multi-centre, double-blind, randomized trial of Saroglitazar 4 mg compared to placebo in patients with nonalcoholic steatohepatitis. Hepatol Int. 2020;14:S326. doi: 10.1007/s12072-020-10016-2
- Gawrieh S, Noureddin M, Loo N, et al. A phase 2, prospective, multicentre, double-blind, randomized study of Saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis (EVIDENCES IV). Hepatology. 2019;70:1484A.
- Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26:128-141. doi: 10.3350/cmh.2019.0001n
- Jain MR, Giri SR, Bhoi B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018;38:1084-1094. doi: 10.1111/liv.13634